Active with AF Finding the right balance
Created 10/16/2015 Dr. Matthew Fay: Westcliffe Medical Group
Dr Matthew Fay GP Principal The Willows Medical Practice:-Queensbury
GPwSI and Co-Founder Westcliffe Cardiology Service
Clinical Partner The Westcliffe Medical Group
Declaration of interests
• The practice has received funding from: Abbott, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Dawn, INRStar, Medtronic, Oberoi Consulting, Pfizer, Roche, Sanofi-Aventis, Servier.
• An advisor to: AF Association, Anticoagulation Europe, Arrhythmia Alliance, Heart Valve Voice, National Stroke Association, Syncope Trust
• A trustee of Thrombosis UK
Dabigat ran etexilate for the
prevent ion of st roke and systemic
embolism in at rial f ibrillat ion
Issued: March 2012
NICE technology appraisal guidance 249
guidance.nice.org.uk/ta249
NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and
applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to
the methods of technology appraisal' (2008). More information on accreditation can be viewed at
www.nice.org.uk/accreditation
© NICE 2012
Rivaroxaban for the prevent ion of
st roke and systemic embolism in
people with at rial f ibrillat ion
Issued: May 2012
NICE technology appraisal guidance 256
guidance.nice.org.uk/ta256
NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and
applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to
the methods of technology appraisal' (2008). More information on accreditation can be viewed at
www.nice.org.uk/accreditation
© NICE 2012
Apixaban for prevent ing st roke and
systemic embolism in people with
nonvalvular at rial f ibrillat ion
Issued: February 2013
NICE technology appraisal guidance 275
guidance.nice.org.uk/ta275
NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and
applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to
the methods of technology appraisal' (2008). More information on accreditation can be viewed at
www.nice.org.uk/accreditation
© NICE 2013
Atrial f ibrillat ion: the management
of at rial f ibrillat ion
Issued: June 2014
NICE clinical guideline 180
guidance.nice.org.uk/cg180
NICE has accredited the process used by the Centre for Clinical Practice at NICE to produce
guidelines. Accreditation is valid for 5 years from September 2009 and applies to guidelines produced
since April 2007 using the processes described in NICE's 'The guidelines manual' (2007, updated
2009). More information on accreditation can be viewed at www.nice.org.uk/accreditation
© NICE 2014
NICE
Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of
thrombophilia testing
June 2012
Deep vein thrombosis
Atrial f ibrillat ion: t reatment and
management
Issued: July 2015
NICE quality standard 93
guidance.nice.org.uk/qs93
© NICE 2015
NICE Quality Standard 93
Statement 1
• Adults with non-valvular atrial fibrillation and a CHA2DS2-VASc stroke risk score of 2 or above are offered anticoagulation
NICE Quality Standard 93
Statement 2
• Adults with atrial fibrillation are not prescribed aspirin monotherapy for stroke prevention
NICE Quality Standard 93
Statement 3
• Adults with atrial fibrillation who are prescribed anticoagulation discuss the options with their healthcare professional at least once a year.
NICE Quality Standard 93
Statement 4
• Adults with atrial fibrillation taking a vitamin K antagonist who have poor anticoagulation control have their anticoagulation reassessed
NICE Quality Standard 93
Statement 6 (Developmental)
• Adults with atrial fibrillation on long term vitamin K antagonist therapy are supported to self-manage with a coagulometer
NICE Quality Standard 93
Statement 5
• Adults with atrial fibrillation whose treatment
Diet
Coffee
Activity
Sleep
Exercise
Travel
Sex
Medication
Anticoagulation
Anticoagulation
Warfarin
Anticoagulation
Not Warfarin
